【摘要】 目的 评价达纳康(Egb761)治疗血管性认知功能障碍的临床疗效和安全性。方法 110例血管性认知功能损害的病人随机分配到治疗组和对照组;治疗组服用达纳康,每次80 mg,每日3次,而对照组服用丹参片,每次2片,每日3次,疗程均为3个月,并应用MMSE和ADL量表评价其疗效。结果 治疗组MMSE评分增加较对照组多2.38,差异有统计学意义(P<0.01);治疗组ADL评分减少较对照组多0.41,但差异无统计学意义(P>0.05)结论 达纳康治疗血管性认知功能损害安全有效。更多还原

【Abstract】 Objective To assess the efficacy and safety of Tanakan in vascular cognitive impairment(VCI). Methods One hundred and ten patients with VCI were assigned randomly to treatment with Tanakan or Dan-shen. The test group was treated with Tanakan (80 mg Tid) and the control group was treated with Dan-shen (2 tables Tid). The duration of therapy was three months, MMSE and ADL were used to measure outcome. Results The Tanakan group had a MMSE score 2.38 points better than the Dan-shen group (P < 0.01) and an ADL score 0.41 points lower than the Dan-shen group (P >0.05). There was significant differenc between Tanakan group and Dan-shen group in VCI. Conclusions Tanakan is safe and appears capable of improving the cognitive performance of VCI patients.更多还原